Stock events for Amneal Pharmaceuticals, Inc. (AMRX)
Over the past six months, Amneal Pharmaceuticals' stock price has increased by 37.63%, and over the past year, it has increased by 50.57%. Key events impacting the stock price include the Q4 and Full Year 2025 Earnings Report, which exceeded EPS estimates but provided slightly below-expected revenue guidance, Q3 2025 Earnings, which led to raised guidance, and Q2 2025 Earnings, which showed strong growth and higher guidance. Analyst ratings have generally been positive, with "Buy" or "Overweight" ratings and price targets ranging from $13.00 to $17.00.
Demand Seasonality affecting Amneal Pharmaceuticals, Inc.’s stock price
The timing of revenue for key products and new launches can cause a 1% decrease in Affordable Medicines net revenue, suggesting some products may experience seasonal impacts that affect quarterly comparisons.
Overview of Amneal Pharmaceuticals, Inc.’s business
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing, manufacturing, and distributing essential medicines. It operates in the Healthcare sector, specifically in the Pharmaceuticals: Major industry, and is structured into three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment focuses on generic and complex pharmaceutical products, including various dosage forms and delivery systems. The Specialty segment develops and distributes branded pharmaceutical products, particularly for CNS and endocrine disorders. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services primarily to governmental agencies.
AMRX’s Geographic footprint
Amneal Pharmaceuticals has a global presence with operations in the United States, India, and Ireland. The company's headquarters are located in Bridgewater, New Jersey, USA. It maintains manufacturing facilities in the United States, India, and Ireland, supported by a global supply chain.
AMRX Corporate Image Assessment
Information specifically detailing events that have affected Amneal Pharmaceuticals, Inc.'s brand reputation (positive or negative) in the past year is not readily available in the provided search results.
Ownership
Amneal Pharmaceuticals, Inc. has a mixed ownership structure, with approximately 49.08% of the stock held by institutional shareholders such as Vanguard Group Inc. and BlackRock, Inc. Individuals hold approximately 46.21% of the shares, with Tushar Bhikhubhai Patel being the largest individual shareholder. Insiders collectively own 118.37% of the company's stock, including significant holdings by Tushar Bhikhubhai Patel and Gautam Patel.
